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Objective: Fish or fish oil consumption may increase levels of total and high molecular 49 
weight (HMW) adiponectin, a hormone associated with anti-inflammatory and insulin-50 
sensitising effects, however it is not known if the effects of the food and supplement are the 51 
same. The aim of this study was to compare the effect of consuming fish and fish oil 52 
supplements on plasma total and HMW adiponectin concentrations in overweight human 53 
subjects.  54 
Materials/Methods: 29 overweight participants underwent a two week run-in period, followed 55 
by a four week isocaloric dietary intervention which provided 1.8g of long chain omega-3 56 
polyunsaturated fatty acids (LC n-3 PUFA) in the form of either fish or fish oil supplements. 57 
Primary outcomes were changes in plasma total and HMW adiponectin. Secondary outcomes 58 
were changes in anthropometric variables, plasma insulin and glucose levels, and dietary 59 
intakes.  60 
Results: Changes in plasma HMW adiponectin during the intervention period were 61 
significantly different between groups (p=0.009). Mean HMW adiponectin increased by 62 
0.29ug/mL in the ‘fish’ group and decreased by 0.60ug/mL in the ‘supplement’ group. 63 
Similar trends were seen for total adiponectin however these did not reach statistical 64 
significance. There were no significant changes in other anthropometric and biochemical 65 
variables. Dietary data suggested the ‘fish’ group significantly increased their fish (p=0.001) 66 
and dietary LC n-3 PUFA (p=0.001) consumption over the course of the study. 67 
Conclusions: Short-term consumption of fish and fish oil supplements did not have the same 68 
effects on HMW adiponectin levels. The impact of fish intake on HMW adiponectin levels 69 




Keywords: omega-3, adipocyte hormone, dietary intervention 72 
List of abbreviations used in this manuscript 73 
BMI: body mass index 74 
DH: diet history 75 
DHA: docosahexaenoic acid 76 
EPA: eicosapentaenoic acid 77 
FTO: fat mass and obesity-associated 78 
HMW: high molecular weight 79 
IQR: interquartile range 80 
LC n-3 PUFA: long chain omega-3 polyunsaturated fatty acids 81 
PPARγ: peroxisome proliferator activated receptor γ 82 
SD: standard deviation 83 
SNP: single nucleotide polymorphisms 84 
  85 
Introduction 86 
 87 
Adiponectin, a hormone secreted by adipocytes, is known to play a role in mediating 88 
inflammation, as well as having anti-obesity and insulin sensitising effects [1, 2]. 89 
Adiponectin levels are lower in individuals who are obese [3] or type II diabetic [4], and 90 
treatment with adiponectin in animal models improves insulin sensitivity and promotes 91 
weight loss [2, 5]. Adiponectin circulates in multimers of varying metabolic weights, 92 
including high molecular weight (HMW) adiponectin [6]. HMW is thought to be the more 93 
physiologically active form of adiponectin, with HMW adiponectin levels found to be a better 94 
predictor of insulin sensitivity and other components of the metabolic syndrome than total 95 
adiponectin concentrations [7].   96 
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There is evidence to suggest that consumption of either fish or fish oil supplements 97 
rich in long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) can increase 98 
adiponectin levels in both animal models [8-11] and humans [12-17]. This effect is thought to 99 
be mediated by the activation of Peroxisome Proliferator Activated Receptor γ (PPARγ) by 100 
LC n-3 PUFA, which results in increased adiponectin synthesis in adipose tissue [18].  101 
It is currently unclear whether fish and fish oil supplements have the same effect on 102 
adiponectin synthesis and secretion. The concept of food synergy proposes that interaction 103 
between the bioactive compounds present in foods may be responsible for providing 104 
additional health benefits, over and above those provided by the actions of the single 105 
nutrients in these foods [19, 20]. In accordance with this concept, research suggests that 106 
whole fish may have additional health benefits than those provided by fish oil alone [21, 107 
22].To date, however, only very few studies have compared the effects of fish and fish oil on 108 
any health outcome, including circulating adiponectin concentrations. Futhermore, most 109 
studies investigating the effects of foods on adiponectin levels have failed to measure 110 
changes in HMW adiponectin, despite its known physiological importance.  111 
There is also evidence from recent human reports that single nucleotide 112 
polymorphisms (SNPs) in the gene encoding for adiponectin, ADIPOQ, can influence 113 
circulating levels of adiponectin, with individualscarrying the C allele of the ADIPOQ SNP 114 
rs266729 have been found to have lower levels of circulating adiponectin than those 115 
homozygous for the G allele [23]. Similarly, SNPs in the fat mass and obesity-associated 116 
(FTO) gene may influence adiponectin levels as well as health outcomes [24, 25], and 117 
Caucasian women who were homozygous for the A allele of the FTO SNP rs9939609 have 118 
been found have lower circulating levels of adiponectin than those homozygous for the T 119 
allele [24]. Therefore, such variations have the potential to pre-dispose individuals to altered 120 
levels of adiponectin and could thus confound the results of dietary interventions. However, 121 
6 
 
no known study assessing the effect of fish or LC n-3 PUFA on adiponectin levels has 122 
measured SNPs in ADIPOQ or FTO genes. 123 
 The primary aim of this study was to compare the effects of consumption of fish and 124 
fish oil supplements, providing a similar amount of LC n-3 PUFA, on total and HMW 125 
adiponectin levels in overweight humans.  A secondary aim was to determine whether these 126 
effects were modified by the participant’s ADIPOQ and/or FTO genotype.  127 
 128 
Materials and Methods 129 
 130 
Study design: A six week pilot study was conducted with overweight adults randomised to 131 
one of two parallel arms: fish diet group (‘fish’) and fish oil group (‘supplement’). 132 
Participants were block randomised by gender and body mass index (BMI) category (25-133 
30kg/m2 and 30-35kg/m2). Both groups underwent a two week run-in period (t= -2-0 weeks), 134 
designed to orient them to the study protocol and to observe any reductions in weight 135 
following commencement of the study. Following this two week run-in period, both groups 136 
commenced the four week dietary intervention (t=0–4 weeks). Primary outcomes were 137 
change in total and high molecular weight (HMW) plasma adiponectin concentrations. 138 
Secondary outcomes included changes in anthropometric variables, fasting insulin and 139 
glucose concentrations and dietary intakes. 140 
 141 
Participants were recruited via advertisements sent to University of Wollongong 142 
general and academic staff and flyers distributed at University of Wollongong events.  143 
Inclusion criteria: aged 18–65 years, willing to consume fish, BMI >25 and <37kg/m2, waist 144 
circumference >94cm for men, >80cm for women, generally well. 145 
7 
 
Exclusion criteria: Diabetes mellitus, impaired renal function, smoking, not weight stable for 146 
the past six months, food allergies or habits inhibiting compliance with the study design, 147 
illiteracy and inadequate conversational English, currently taking medications including 148 
thiazolidinediones, valproic acid, ACE inhibitors, and glucocorticoids, pregnancy/lactation, 149 
high consumption of fish (>two serves per week) 150 
 151 
Dietary intervention: For six weeks both groups were advised to consume an isocaloric diet 152 
for weight maintenance (meeting estimated energy requirements [26] with 1.25 physical  153 
activity factor) and consisting of 25% protein, 45% carbohydrate, and 30% fat. Diets referred 154 
to low fat staple foods (fruit, vegetables, cereals, lean meat, low fat milk and yoghurt) and 155 
small amounts of nuts, seeds, spreads and oils. Due to the effects of changes in alcohol 156 
consumption on adiponectin levels [27, 28], participants were advised to maintain their 157 
normal level of alcohol consumption over the course of the study. Following the two week 158 
run-in period, participants in the ‘fish’ group were provided with three serves of 135g salmon 159 
(Birds Eye Atlantic Salmon Fillets, Simplot Australia), two serves of 66g sardines (adjusted 160 
for percentage fish in total canned product; John West Sardines in Tomato Sauce, Simplot 161 
Australia) and one serve of 55.1g tuna (adjusted for percentage fish; John West Tuna 162 
Tempters Lemon and Cracked Pepper, Simplot Australia) per week for four weeks. Due to an 163 
inability to consume sardines, one participant was provided with four serves of 135g salmon 164 
and one serve of 55.1g tuna per week. The fish provided was designed to contribute 165 
approximately 1.86g of LC n-3 PUFA per day (approximately 812mg Eicosapentaenoic acid 166 
[EPA] + 1044mg Docosahexaenoic acid [DHA]). During the dietary intervention period, 167 
participants in the ‘supplement’ group were given three fish oil supplements per day, to 168 
provide 1.8g of total LC n-3 PUFA (1055.1mg EPA + 744.9mg DHA; Blackmores Omega 169 
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Daily). Participants in the ‘supplement’ group were not given any specific advice regarding 170 
fish consumption. 171 
 Diet histories (DH) interviews [29] were collected at t= -2 weeks and t=4 weeks to 172 
identify changes from habitual diets. Dietary intake was calculated using the Foodworks 173 
nutrient analysis software (Xyris Pty Ltd, Highgate Hill, QLD, Australia, Version 6, 2009), 174 
using the ‘AUSNUT2007 Brands’ and ‘AUSNUT2007 Foods’ nutrient databases [30]. Fish 175 
intake was calculated as grams of fish consumed per week. 176 
All remaining fish and supplements were collected at the end of the study to measure 177 
compliance. Returned supplements were used to calculate LC n-3 PUFA intake in the 178 
‘supplement’ group in addition to dietary LC n-3 PUFA measured by DH interview.  179 
 All participants were advised to maintain their normal level of physical activity over 180 
the duration of the study. Habitual physical activity was assessed prior to the run-in period 181 
(t= -2 weeks) and at the end of the study (t=4 weeks) via the Baecke questionnaire [31]. 182 
 183 
Anthropometry: Body weight and percentage body fat were measured in an upright position 184 
at t= -2, 0, 4 weeks, in minimal clothing and without shoes using scales with a bioelectrical 185 
impedance component (Tanita TBF-662). Waist circumference was measured at t= -2, 0, 4 186 
weeks with a flexible tape measure. 187 
 188 
Insulin, glucose, plasma fatty acids and adiponectin: were measured in the morning after an 189 
overnight fast at t= -2, 0, 4 weeks. Insulin and glucose levels were measured by a quality 190 
assured pathology laboratory (Southern IML Pathology), whilst plasma fatty acids were 191 
analysed by the Functional Food Group, FOODplus Research Centre, School of Agriculture, 192 
Food and Wine, University of Adelaide as described by Tu et al. [32]. Plasma total and high 193 
molecular weight (HMW) adiponectin concentrations were measured using a multimeric 194 
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enzyme-linked immunosorbent assay (Alpco Diagnostics Inc, Salem, NH). All adiponectin 195 
concentrations were measured in duplicate and any questionable results were re-tested. Care 196 
was taken to ensure all samples from the same participant were measured in the same assay 197 
run.   198 
 199 
For the SNP analysis in ADIPOQ and FTO genes, saliva samples were collected for 200 
DNA extraction (Oragene, DNA Genotek, USA) at t=4 weeks. Due to the known ethnic 201 
variations in the prevalence of the tested SNPs and their functional polymorphisms [33, 34], 202 
saliva samples were collected only from participants of Caucasian ethnicity (n=25). Analysis 203 
of SNPs in ADIPOQ (rs266729) and FTO (rs9939609, rs8050136) was performed in 204 
duplicate using MALDI-TOF mass spectrometry (Sequenom MassARRAY iPLEX Platform).  205 
Statistical analysis: Data was analysed using SPSS (version 17.0, SPSS Chicago, IL, 2008). 206 
Normality of the data was determined using the Shapiro-Wilks test. Mean and standard 207 
deviation (SD) of all parametric variables were calculated, whilst median and inter-quartile 208 
range (IQR) were calculated for non-parametric variables.  209 
As the run-in period (t= -2–0 weeks) was designed to stabilise measures, reduce the 210 
within-participant variation and minimise the possibility of regression to the mean, the 211 
anthropometric and biochemical data from this period was not included in the analysis. As 212 
the literature suggests that research should focus on the change in adiponectin levels over 213 
time rather than single measures at an individual time point [35], changes in total and HMW 214 
adiponectin from t=0 to t=4 weeks were calculated and compared between groups via an 215 
independent samples t-test and Mann-Whitney test for parametric and non-parametric data 216 
respectively. This approach has been previously used in the adiponectin literature [15, 36]. 217 
Changes in total and HMW adiponectin from t=0 to t= 4 weeks within groups were calculated 218 
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and compared via a paired samples t-test and a Wilcoxan signed ranks test for parametric and 219 
non-parametric data respectively 220 
Differences in other biochemical and anthropometric variables over time and between 221 
groups were measured via mixed between-within subjects ANOVA for parametric variables. 222 
For non-parametric dietary data, differences between groups were measured via a Mann-223 
Whitney test, whilst differences in biochemical and anthropometric variables within groups 224 
over the duration of the intervention period (t=0–4 weeks) were measured via Wilcoxon 225 
signed ranks test. Differences in dietary variable and the Baecke questionnaire over the 226 
duration of the pilot study and between groups were also measured in this way. Due to a 227 
violation of the minimum cell frequency assumption of the Pearson’s chi-square analysis, 228 
Fisher’s exact test was used to determine if there was a significant difference between the 229 
allelic frequencies of SNPs in ADIPOQ and FTO in the ‘fish’ and ‘supplement’ groups. 230 
Compliance to recommended fish and supplement intake was measured as the number 231 
of fish or supplements consumed (calculated from returned products) as a percentage of the 232 
number of fish or supplements recommended provided. Mean and SD compliance of the 233 
study sample was then determined. 234 
 235 
Ethical approval was granted by the University of Wollongong Human Research 236 




Of the n=93 individuals who expressed an interest in the study, n=30 met the 241 
inclusion criteria and were able to meet study requirements, and n=28 were present at t=0 and 242 
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4 weeks (Figure 1). Total and HMW adiponectin results were excluded for one participant at 243 
all time points as a result of implausible findings.  244 
There were no significant differences in total and HMW adiponectin levels between 245 
study groups at t = 0 (Table 1). Change in HMW adiponectin over the intervention period 246 
was significantly different (p=0.009) between the ‘fish’ and ‘supplement’ groups. In the 247 
‘supplement’ group, there was a significant decrease in HMW adiponectin levels over the 248 
duration of the study (p=0.026), whilst there was no change in plasma HMW adiponectin 249 
levels in the ‘fish’group.. There were no significant changes in total adiponectin over the 250 
duration of the study in either of the treatment groups and total adiponectin concentrations 251 
were not different between the ‘fish’ and ‘supplement’ groups at any timepoint.  252 
The percentage of EPA + DHA in plasma phospholipids increased significantly over 253 
the intervention period in both the ‘fish’ (p=0.001) and ‘supplement’ groups (p=0.001), but 254 
there was no significant difference between the groups at t=4 weeks (p=0.114) (Table 2). 255 
There were no significant differences within or between groups in any other anthropometric 256 
or biochemical variable. There was also no significant difference between groups in the 257 
allelic frequencies of SNPs in ADIPOQ and FTO genes (Table 3). 258 
The ‘fish’ group reported significantly increasing fish intake (p=0.001), and were 259 
consuming significantly higher amounts of fish than the ‘supplement’ group at the end of the 260 
intervention (p<0.001). Similarly, significantly higher intakes of LC n-3 PUFA from the diet 261 
were reported by the ‘fish’ group (p<0.0001), however there was no significant difference 262 
between the total LC n-3 PUFA intake from both dietary and supplement sources combined 263 
between the ‘fish’ and ‘supplement’ groups (p=0.285). During the intervention both the ‘fish’ 264 
and ‘supplement’ groups reported a reduced percentage energy intake from total and 265 
saturated fat (time effect: p=0.005, p=0.001 respectively) (Table 4). A significant interaction 266 
effect was also seen for percent energy from polyunsaturated fat (p=0.001).  267 
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Mean and SD compliance for the ‘fish’ and ‘supplement’ groups was 87.51+16.54% 268 




 The results of this study suggest that short-term consumption of fish and fish oil 273 
supplements do not have the same effect on HMW adiponectin levels in overweight humans. 274 
Over the course of a dietary intervention which incorporated the same amount of LC n-3 275 
PUFA provided by either fish or fish oil, a significantly different change in HMW 276 
adiponectin was found between groups; This was due to a small increase in HMW 277 
adiponectin in the ‘fish’ group, whilst the ‘supplement’ group exhibited a significant decrease 278 
in HMW adiponectin concentraitons following the dietary intervention, there was no change 279 
in HMW adiponectin in those receiving the same level of n-3 LCPUFA from fish for the 280 
same period. A similar pattern was seen for total adiponectin; however this did not reach 281 
statistical significance.  These changes occurred whilst factors known to be associated with 282 
adiponectin levels, such as weight and insulin levels [37], remained relatively constant.   283 
 This data suggests that the health benefits of fish may not be limited to the LC n-3 284 
PUFA content alone. It is currently not known why differential effects on HMW adiponectin 285 
were seen for fish and LC n-3 PUFA supplement consumption, and whilst this study was not 286 
designed to test mechanisms for change, some possibilities can be proposed. As a whole 287 
food, fish consists of a variety of additional nutrients and bioactive ingredients which could 288 
impact upon health. Consumption of fish protein has been linked to improvements in insulin 289 
sensitivity [38] and insulin response [39]. Furthermore, other components present in fish such 290 
as selenium and vitamin D have also been associated with a range of health benefits in 291 
humans [40, 41]. Whilst there has been no research conducted specifically investigating the 292 
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influence of consumption of these nutrients on adiponectin levels, due to their known health 293 
benefits and as the intervention diets in the present study were matched for total LC n-3 294 
PUFA content, it is reasonable to suggest that compounds such as these, in addition to the LC 295 
n-3 PUFA, may have played a role in the changes in HMW adiponectin levels. The 296 
differential effects of fish and fish oil found in the present study are supported by research by 297 
Cobiac et al. [21], who found improvements in haemostatic factors in hyperlipidemic men 298 
following fish, but not fish oil, consumption. 299 
No previous research has compared the effects of fish and fish oil supplements on 300 
HMW adiponectin and only one study has done so using total adiponectin as an outcome. 301 
Ramel et al. [42] provided participants with salmon, cod, fish oil supplements or a control 302 
diet of chicken over 12 weeks and found a reduction in total adiponectin in all groups, with 303 
no significant difference between groups. However, this study did not investigate changes in 304 
HMW adiponectin levels, which have been found to increase in concentration post-weight 305 
loss even when no changes in total adiponectin were seen [43]. Furthermore, unlike the 306 
present study, Ramel et al. [42] did not match the LC n-3 PUFA provided by the salmon and 307 
fish oil diets, making comparisons between the whole food and supplement problematic.  308 
Whilst there is a paucity of literature comparing the effects of fish and fish oil on 309 
HMW adiponectin, several studies have examined the impact of either fish or fish oil 310 
consumption on total adiponectin with varying results. Guebre-Egziabher et al. [12]; Kondo 311 
et al. [16]; and Lara et al. [14] found increases in total adiponectin levels following fish 312 
consumption, whilst Krebs et al. [13]; Sneddon et al. [15]; and Gammelmark et al. [17] found 313 
similar results after supplementation with fish oil. A limitation of these studies however, is 314 
that none examined the effect of fish consumption on HMW adiponectin. Only one previous 315 
study has examined the influence of either fish or fish oil supplements on HMW adiponectin, 316 
and did not see a significant effect of fish oil [44]. Given the known biological importance of 317 
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HMW adiponectin, it is important to investigate this component in addition to total 318 
adiponectin, as non-significant changes in total adiponectin could mask a significant change 319 
in the HMW multimer, as was found in the present study. 320 
In the present study, a significant decrease in total and HMW adiponectin 321 
concentrations was found in the ‘supplement’ group. This contrasts with the results of 322 
previous studies which have found  increases in total adiponectin levels following 323 
supplementation with fish oil [13, 15, 17]; however this may be the result of methodological 324 
issues in previous research, such as the use of an ad libitum study diet [15], and failing to 325 
measure dietary LC n-3 PUFA intake [13, 15, 17]. A strength of the current study was that 326 
dietary variables were controlled for through a prescribed study diet, which were confirmed 327 
through dietary assessment. The DH data indicated the ‘fish’ group consumed significantly 328 
higher amounts of LC n-3 PUFA from the diet than the ‘supplement’ group at 6 weeks (Table 329 
2). The inclusion of total LC n-3 PUFA consumed (calculated from returned supplements) 330 
suggested that both groups consumed similar amounts of LC n-3 PUFA from dietary and 331 
supplement sources as planned. This was supported by the plasma fatty acid analysis, which 332 
found no difference in levels of omega-3 or EPA + DHA between groups at the end of the 333 
intervention.    334 
Genetic analysis performed in the present study confirmed that there was no 335 
difference between the allelic frequency of SNPs in an adiponectin encoding gene and a gene 336 
associated with risk of obesity in the ‘fish’ and ‘supplement’ groups. These SNPs, which 337 
have been associated with alterations in circulating levels of adiponectin and risk factors for 338 
the metabolic syndrome and its associated diseases [23, 24, 34] could potentially confound 339 
the results of this study if variations existed between tested groups. However, similar 340 
genotypic and allelic frequencies of the tested SNPs found in both study groups suggests the 341 
findings of the present study were due to dietary changes rather than genetic variation 342 
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between groups. This is a strength of the current study, as no previous studies have 343 
investigated genetic variation between groups. 344 
This study was limited by its small sample size and the short time period of the 345 
dietary intervention. However, as no previous research has compared the effects of fish and 346 
fish oil on HMW adiponectin, or indeed, many other health outcomes, this study has helped 347 
to establish proof of concept in this area. The lack of a separate control group is also a 348 
limitation of this study; however the run-in period addressed some of this problem by 349 
eliminating the effect of weight loss following commencement of dietary advice.  350 
 This study, which was the first to compare the effects of fish and fish oil supplements 351 
on total and HMW adiponectin, has shown that short-term consumption of fish and 352 
supplements do not have the same effect on this hormone. This finding was made in the 353 
absence of confounding factors such as dietary and genetic variations between groups.   354 
Whilst the changes in HMW adiponectin found in this study were relatively small, the 355 
differing patterns seen with fish and fish oil consumption imply dissimilar biological effects 356 
which necessitate further investigation. 357 
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Table 1: Mean + SD [median (IQR)] change in total and HMW adiponectin levels from t=0 to t=4 weeks 
1Paired samples t-test                                  2Wilcoxon signed ranks test                       
3Independent samples t-test                        4Mann-Whitney test 




t=0 t=4 Change (t=0 













6.93 + 2.82 
[6.69 (4.43 
– 8.38)] 
7.74 + 3.36 
[7.57 (4.97 – 
10.10)] 
0.81 + 1.95 
[0.34 (-0.37 – 
1.01)] 
0.1801 6.60 + 2.34 
[6.25 (4.31 
– 8.47)] 
6.46 + 2.51 
[5.96 (4.34 
– 8.91)] 
-0.14 + 2.05 
[0.51 (-1.19 – 
1.44)] 





3.63 + 2.45 
[3.62 (1.25 
– 5.00)] 
3.92 + 2.96 
[3.62 (1.07 – 
5.32)] 
0.29 + 0.97 
[0.01 (-0.25 – 
0.40)] 
0.3211 3.39 + 2.07 
[2.63 (1.61 
–  4.96)] 
2.81 + 1.80 
[2.12 (1.30 
– 4.25)] 
-0.58 + 1.18    
[- 0.63 (-0.99 –  
-0.22)] 




Table 2: Anthropometric and biochemical variables at t= -2, 0 and 4 weeks 
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1Data available for n = 27 participants (n=13 fish, n=14 supplements) 
2Data excluded for n = 1 participant due to machinery malfunction (data available for: n=13 ‘fish’, n=14 ‘supplements’) 
3Mann-Whitney test                                4Independent t-test 
















1Fisher’s Exact Test 
2G allele associated with decreased levels of adiponectin 43 
3A allele associated with increased risk of obesity 27 
 ‘Fish’ ‘Supplement’ P-value1 
SNPs Genotypes Genotypes  
rs266729 
(ADIPOQ) 
CC GC/GG2 CC GC/GG2  
0.695 7 6 5 7 
rs9939609 
(FTO) 
TT AT/AA3 TT AT/AA3  
 
0.673 
3 10 4 8 
rs8050136 
(FTO) 
CC CA/AA3 CC CA/AA3  
 
0.673 
3 10 4 8 
27 
 
Table 4: Reported daily dietary intake and physical activity levels at t= -2 and 4 weeks 
 ‘Fish’ ‘Supplement’ 
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   t=-2 wks 
  
   t=4 wks 
(diet only) 
   t=4 wks 











341.07 (150.20 – 
499.26) 
328.11 (1898.20 – 
1957.03) 
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2.64 (1.73 – 5.33) 
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1Mann-Whitney test                            2Mann-Whitney test (compared to dietary LC n-3 PUFA at t= -2 weeks) 
3Wilcoxon signed ranks test                              4Mixed between-within subjects ANOVA 
5Independent t-test 






































Figure 1: Enrolment, randomisation and available data for study participants over the 
duration of the study 
Expressed interest in study 
(n=93) 
Enrolled and randomised (n=30) 
Total (n=30)     ‘Fish’                   
(n=15)   
‘Supplement’                   
(n=15)   
Withdrew prior 




   
‘Supplement’ (n=1) 
-due to study time 
commitment 
t= -2 weeks 
(n=29)     
‘Fish’ 
(n=15) 
‘Supplement’                   
(n=14)   
Withdrew (n=1)     ‘Fish’ 
(n=1) 
-due to a fear of needles 
   ‘Supplement’ 
(n=0) 
    
t=0 weeks 
(n=28)     
‘Fish’ (n=14) 
-percent body fat not 
available (n=1) 
-blood analyses not 
available (n=1) 




‘Supplement’                   
(n=14)   
t=4 weeks 




- physical activity not 
available (n=1) 
- excluded due to implausible 
adiponectin results (n=1) 
 
Genetic analysis (n=13) 
              
 
‘Supplement’                   
(n=14)   
Genetic analysis 
(n=12) 
